Redeye comments on the takeover bid from OsteoCentric.
Redeye provides a brief comment on FMG’s downward revision of its full-year guidance.
OEM challenges delay ramp-up, again CTT continues to suffer from supply chain challenges at its cust...
Studentbostäder i Norden rapporterar ett andra kvartal i linje med våra förväntningar påverkat av sä...
Q2 expectations We expect Q2 sales of EUR 43m, +1% y-o-y and +11% q-o-q.
Redeye is encouraged by FluoGuide announcing a non-exclusive collaboration with global medtech compa...
Solid growth, profitability on previous year levels Oriola posted solid growth figures in Q2, whil...
Order backlog at its highest level since Q2/23 Consti’s steady development continued during the se...
Redeye states that Acconeer's Q2 2025 report fell short of its expectations for both sales and EBITD...
Redeye updates its estimates and fair value range following CTEK’s Q2 report, which was released las...
Redeye updates its estimates and valuation following Sdiptech’s Q2 2025 report, which was broadly in...
Redeye comments on IRLAB’s announcement of the outcome of its rights issue, which raised gross proce...
Redeye updates its estimates and valuation following the Q2 2025 report from Momentum Group.
Redeye updates its estimates and valuation following Tradedoubler’s Q2 2025 report.
Redeye interviews Lagercrantz’s CEO, Jörgen Wigh. We discuss the company’s solid Q1 figures, recent ...
Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 8%, with the ...
Redeye maintains a positive stance on Dynavox following another standout quarter.
Redeye provides an update following Truecaller’s Q2 2025 report, which came in somewhat softer than ...
Paving services delivering Infrea delivered a mixed Q2, with sales 5% above ABGSCe.
Redeye updates its estimates and fair value range following Arise’s Q2 report.